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The anterior gradient protein-2 (AGR2) is inducible by oestrogen and itself can induce metastasis in a rat model for breast cancer.
Here, a rabbit antibody to recombinant human AGR2 was used to assess its prognostic significance in a retrospective cohort of 351
breast cancer patients treated by adjuvant hormonal therapy. The antibody stains 66% of breast carcinomas to varying degrees. The
percentage of positive carcinoma cells in tumours directly correlates with the level of AGR2 mRNA (Spearman’s rank correlation,
P¼0.0007) and protein (linear regression analysis r
2¼0.95, P¼0.0002). There is a significant association of staining of carcinomas for
AGR2 with oestrogen receptor a (ERa) staining and with low histological grade (both Fisher’s Exact test Po0.0001). In the ERa-
positive cases, but not the ERa-negative cases, when subdivided into the separate staining classes for AGR2, there is a significantly
progressive decrease in patient survival with increased staining (log rank test, P¼0.006). The significant association of staining for
AGR2 with patient death over a 10-year period (log rank test P¼0.007, hazard ratio¼3) only becomes significant at 6 years of
follow-up. This may be due to the cessation of adjuvant hormonal therapy at an earlier time, resulting in adverse re-expression of the
metastasis-inducing protein AGR2.
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Molecules involved in metastasis offer a potential source for the
identification of useful markers of prognosis for breast cancer,
since the majority of deaths are attributable to the formation of
secondary tumours at site or sites distant to the primary tumour
(Kamby, 1990; EBCTCG, 2005). Recently, anterior gradient
protein-2 (AGR2; previously hAG-2), human homologue of the
Xenopus laevis cement gland protein, XAG-2, has been identified,
by suppression subtraction hybridisation, as being expressed at a
higher level in the human breast cancer cell line MCF-7 than in the
benign cell line Human mammary 123 (Liu et al, 2005).
Transfection of AGR2 cDNA into a benign rat mammary cell line,
Rat mammary (Rama) 37, induced a metastatic phenotype in vivo,
such that when the cells were injected into the mammary fat pads
of syngeneic rats, the majority (77–82%) developed lung
metastases (Liu et al, 2005). In similar experiments, the Rama 37
cells have been shown previously to be converted to a metastatic
phenotype by genes encoding the proteins S100A4 (Davies et al,
1993) and osteopontin (Oates et al, 1996). Expression of both of
these proteins, as measured by immunohistochemistry in the
primary tumour, has been shown to correlate with survival in a
cohort of patients with breast cancer, such that higher levels of
expression act as a marker of poor prognosis (Rudland et al, 2000,
2002). However, human AGR2 has been reported previously to be
expressed in the oestrogen receptor alpha (ERa)-positive cell line
MCF-7 but not in an ERa-negative cell line (Thompson and
Weigel, 1998), and preliminary studies in human breast cancers
(Fletcher et al, 2003; Liu et al, 2005) also suggest that AGR2 is
correlated with expression of ERa. There is, therefore, a potential
inconsistency, in that ERa and related markers usually associated
with a better outcome and markers of metastasis with a worse
outcome for breast cancer patients. The aim of this study is to
examine for the first time the expression of AGR2 in specimens of
primary breast carcinomas so as to assess its relationship with
other tumour variables and with patients’ survival in a group of
patients treated by hormonal therapy.
MATERIALS AND METHODS
Patients and specimens
Patients undergoing treatment for invasive breast cancer during
the period 1982 to 1999 at the Royal Liverpool University Hospital
were identified from the Department of Surgery (Martin et al,
1997; de Silva Rudland et al, 2006) and the Cancer Tissue Bank
Research Centre, University of Liverpool (O’Neill et al, 2004). A
total of 351 patients with stage I/II breast cancer were selected;
staging investigations to exclude metastatic disease varied but
generally included chest radiograph and liver function tests. They
had been treated by surgery, with or without radiation, but had not
received systemic chemotherapy. Median age was 64 years (range
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s31–89), their clinical, histological and molecular characteristics
are summarised in Table 1. The vast majority received some
form of adjuvant endocrine treatment. Clinical follow-up data
were recorded by retrospective case-note review and from the
Merseyside Cancer Registry. The outcome measure was
overall survival, with data from surviving patients being censored
at the date last seen. Median follow-up was 85.9 months
(range 0.1–212). For statistical analysis, follow-up was limited to
10 years. Ethical approval for the study was obtained from all
relevant bodies.
Immunohistochemistry
Histological sections (4mm) were cut from the formalin-fixed,
paraffin-embedded specimens and placed onto 3-aminopropyl-
triethoxysilane-coated slides and endogenous peroxidase activity
was blocked using 3% (vv
 1) hydrogen peroxide (H2O2) (Platt-
Higgins et al, 2000). Oestrogen receptor a and progesterone
receptor (PR) status was obtained from review of histopathology
notes (O’Neill et al, 2004) where available, or was determined
immunocytochemically (de Silva Rudland et al, 2006) as described
previously (Platt-Higgins et al, 2000) using a cutoff of 5% to define
the positive and negative groups. Immunohistochemical staining
for AGR2 was performed with affinity-purified AGR2 antibody as
previously described (Liu et al, 2005), with minor modifications.
Slides were preincubated with 2% (wv
 1) bovine serum albumin
(BSA) in phosphate-buffered saline (PBS) for 1h and then
incubated with antibody to AGR2 (diluted 1 in 400 in 2%
(wv
 1) BSA in PBS) for 3h. The bound antibodies were detected
using biotinylated donkey anti-rabbit immunoglobulin (Amer-
sham Biosciences, Bucks, UK) diluted 1 in 200 in 1% (wv
 1) BSA
in PBS and sections were incubated for 1h. The bound antibodies
were visualised as a brown stain by incubating the sections with
3,30-diaminobenzidine (Sigma, Dorset, UK) and 0.075% (vv
 1)
H2O2. They were counterstained with Mayers’ haemalum and
mounted in DPX (Merck, Dorset, UK) (Rudland et al, 2002). The
raising of the rabbit antibody against recombinant human AGR2
and its specificity have been described previously (Liu et al, 2005).
Positive staining was abolished by prior incubation of the
antiserum with 1mgml
 1 human recombinant AGR2 (rAGR2)
protein. Stained slides were analysed independently by two
observers using light microscopy; the percentage of positively
stained malignant cells was estimated by scanning the whole
section at lower power and for at least 10 microscopic fields at
 200 magnification to ensure a representative sample. Staining
for AGR2 was evaluated in six classes. These comprised: negative
(o1% carcinoma cells stained), borderline (1–5% cells stained),
intermediate (5–25% cells stained), moderate (25–50% cells
stained), strong (50–75% cells stained) and very strong (75–
100% cells stained). Where two-way analyses were performed,
the borderline group was combined with the positive cases,
leaving the negative cases as a separate category (unless otherwise
stated).
In controls, the rabbit antiserum was preincubated with
700mgml
 1 human rAGR2 or rAGR3 prior to application to
sections from positively staining specimens and a human AGR2
monoclonal antibody was incubated with sections from 20
different specimens chosen at random. The monoclonal antibody
to AGR2 was raised against a peptide unique to the AGR2
sequence, which did not occur in AGR3 and failed to react with
AGR3 protein (Liu D, Rudland PS, Barraclough R, unpublished
results).
Protein samples and Western blotting
The rAGR2 containing the histidine tag and a protease factor X
cleavage site and the similarly engineered human recombinant
AGR3 (rAGR3) proteins (Liu D, Rudland PS, Barraclough R,
unpublished results) were produced and purified as previously
described (Liu et al, 2005). The apparent molecular weights of 21
and 19kDa, respectively, were consistent with 21 and 19.8kDa
calculated from the amino-acid sequences of the open reading
frames of the cDNA inserts in the expression vectors used (Liu
et al, 2005). Samples of human breast cancer specimens were
frozen in liquid nitrogen and powdered in a pestle and mortar.
They were homogenised in a Polytron homogeniser in a
guanidinium isothiocyanate buffer and fractionated by centrifuga-
tion on a cushion of CsCl as described previously (Anandappa
et al, 1994). The resultant supernatant protein fraction was
dialysed against 10mM NH4CO3, lyophilised, then redissolved in
sample buffer containing 2%(wv
 1) SDS, 2mM phenylmethane-
sulphonyl fluoride, together with glycerol, b-mercaptoethanol and
bromophenol blue. Soluble protein lysates from cell lines were
obtained as described previously (Liu et al, 2005). Samples
containing equal amounts of total proteins were resolved on
0.1% (wv
 1) SDS, 12.5%(wv
 1) polyacrylamide gels together with
molecular weight markers, human rAGR2 and rAGR3 proteins.
The proteins were electrotransferred onto Immobilon PVDF
membranes (Millipore (UK) Ltd, Watford, UK) using a Bio-Rad
Table 1 Clinical, histological and molecular characteristics of primary
breast carcinomas
Characteristic
a Group No
b %
c
Histology Invasive ductal 293 83.5
Invasive lobular 28 8.0
Other 30 8.5
Extent of surgery Wide local excision 249 70.9
Mastectomy 75 21.4
Unknown 27 7.7
Endocrine therapy No 14 4.0
Yes 327 93.2
Unknown 10 2.8
Radiotherapy No 194 55.3
Yes 139 39.6
Unknown 18 5.1
Histological grade I 80 22.8
II 144 41.0
III 119 33.9
Unknown 8 2.3
Tumour size Up to 2cm (T1) 181 51.6
42cm to 5cm (T2) 142 40.5
45cm (T3) 9 2.6
Unknown 19 5.4
Nodal status Negative 141 40.2
Positive 105 29.9
Unknown 105 29.9
Lymphovascular invasion Negative 122 34.8
Positive 107 30.5
Unknown 122 34.8
ERa status Negative 117 33.3
Positive 225 64.1
Unknown 9 2.6
PgR status Negative 79 22.5
Positive 60 17.1
Unknown 212 60.4
aDefined in ‘Materials and Methods’; ERa¼oestrogen receptor a; PgR¼progester-
one receptor.
bNumber of patients.
cPercentage of total patients, out of a total of
351.
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ssemidry transfer apparatus (Bio-Rad Laboratories Ltd, Hertford-
shire, UK). The membranes were incubated with buffer containing
5% (wv
 1) nonfat dried milk for 1h at room temperature, then
with the affinity-purified, in-house rabbit polyclonal anti-human
AGR2 antibody as described previously (Liu et al, 2005). In some
experiments, 1mgml
 1 human rAGR2 was present to provide a
blocked antibody control. After washing and incubating with anti-
rabbit horseradish peroxidase-conjugated IgG, the membranes
were washed and exposed to the Supersignal West Pico
Chemiluminescent Substrate (Pierce Biotechnology Inc., Perbio
Sciences, Cramlington, Northumberland, UK) according to the
manufacturer’s instructions. The chemiluminescent signals were
collected and analysed using the ChemiDoc XRS system (Bio-Rad).
The membranes were reprobed with rabbit polyclonal b-actin
antibody (New England BioLabs (UK) Ltd, Hertfordshire, UK) to
ensure equal protein loading as described previously (Liu et al,
2005). Statistical analyses of Western blotting and immuno-
cytochemical staining were carried out by least-squares regression
using Arcus Pro-Stat Dos version 3.28 software (Medical
Computing, Aughton, UK).
Reverse transcription (RT)–PCR analysis
RNA of suitable quality was available for 84 cases and MCF-7 cell
line RNA was used as a control. RT was performed as described
previously (Livak and Schmittgen, 2001; O’Neill et al, 2004).
Quantitative PCR was performed on a Bio-Rad Icycler PCR Real-
Time PCR machine using 2m1 of a 1:20 dilution of cDNA per
reaction (equivalent to cDNA from approximately 2.5ng of total
RNA). Reactions included 1  IQ SYBR Green Supermix (Bio-Rad)
and 1mM of each PCR primer: AGR2-Forward GAG CCG ATA TCA
CTG GAA GA and AGR2-Reverse CAA GGC CTG ACA GAC AGA
AG; or HPRT-Forward GTG TTG GAT ATA AGC CAG ACT TTG
and HPRT-Reverse AAC TCA ACT TGA ACT CTC ATC TTA GGC.
The PCR reaction consisted of a hot-start Taq Polymerase
activation step of 951C for 3min, followed by either 50 cycles at
941C for 30s/621C for 90s for AGR2, or 36 cycles of 941C for 30s/
641C for 60s for HPRT. Relative expression of mRNA for each gene
was calculated relative to MCF-7 cell line RNA, using the ddCt
method (Livak and Schmittgen, 2001) correcting for the control
gene (HPRT). The identity of PCR products as AGR2 and not
AGR3 was confirmed by DNA sequence analysis as described
previously ((Livak and Schmittgen, 2001; O’Neill et al, 2004).
Statistical analysis
Statistical analyses were performed using the SPSS
s package
(Windows, v.11). The association of immunohistochemical stain-
ing for AGR2 with other tumour variables was assessed using
Fisher’s exact test, two-sided values of P are given. The degree of
agreement between observers was assessed using the kappa (k)-
statistic; a value of 40.61 was taken to be a satisfactory agreement
(Altman, 1991). Curves for overall survival were generated using
the Kaplan–Meier method for censored data, with surviving
patients’ data being censored at the date of their last clinic visit.
Curves from different groups of patients were compared using
both the log rank test and the Wilcoxon (Gehan) statistic.
Unadjusted hazard ratios (HRs)795% confidence intervals (CIs)
were obtained using Cox’s univariate analysis, as described
previously (Rudland et al, 2002). Spearman’s rank correlation
was used as a measure of association between abundance of mRNA
and the degree of immunohistochemical staining, and the
Student’s t-test and the Mann–Whitney U-test were used to
compare the level of AGR2 mRNA between cases which were AGR2
positive and those that were AGR2 negative by immunohisto-
chemistry. Cox’s regression model was used for multivariate
survival analysis (Altman, 1991).
RESULTS
Immunohistochemical staining for AGR2
Immunocytochemical staining of normal breast tissue was usually
negligible (Figure 1A). Staining of primary breast carcinomas for
AGR2 showed great variation from tumour to tumour in the
proportion of cancer cells staining, ranging from none to 490%
(Figure 1B–D). The staining was mainly cytoplasmic and
membranous (Figure 1E). There was some intraobserver varia-
bility, but when tumours were divided into the broad categories of
positively and negatively stained tumours there was agreement in
97.2%, corresponding to a k-score of 0.94. There was a similar
small variation in the assessment of the same histological section
by two observers with agreement in 97.4% of cases, corresponding
to a k-score of 0.94 when divided into the broad categories of
negative and positive. For the specimens where there was disparity,
a consensus score was agreed. Overall, of the 351 cases, 120
(34.2%) were classified as unstained, defined as o1% of carcinoma
cells stained, 61 (17.4%) were ‘borderline’ stained (1–5%
carcinoma cells stained) and the remaining 170 (48.4%) were
stained to some degree by the polyclonal antibody to the AGR2
protein. These were further subdivided into classes of 103 (29.3%)
intermediate (i.e. 5–25% cells stained), 40 (11.4%) moderate (i.e.
25–50% cells stained), 20 (5.7%) strong (i.e. 50–75% stained) and
7 (2.0%) very strong (i.e. 75–100% cells stained). For 20 specimens
chosen at random, the same staining classification was applied to
staining obtained with a MAb specific for AGR2 which did not
react with AGR3 (not shown). Prior incubation of the rabbit
antiserum to AGR2 with pure human rAGR2 (Figure 1F and G),
but not pure human rAGR3 (Figure 1H), abolished staining
completely.
Western blotting and RT–PCR for AGR2
Antiserum to human AGR2 detected a band of 18kDa in
Western blots of extracts from primary breast carcinomas that
were positive in immunocytochemical staining for AGR2
(Figure 2A). This band corresponded in size to that of AGR2
in MCF-7 cells and its appearance was abolished by prior
incubation of the antiserum with human rAGR2 (Figure 2A).
The histidine-tagged human rAGR2 protein containing a protease
factor X cleavage site ran at an apparent molecular weight of
21kDa (Figure 2A). All extracts contained approximately equal
amounts of the constitutively expressed protein. In seven samples
chosen at random, there was a significant correlation between the
level of immunodetectable AGR2 by Western blotting and
the percentage of cells immunocytochemically stained for
AGR2 (linear regression analysis r
2¼0.95, P¼0.0002). The
antiserum to human AGR2 reacted strongly with His-tagged
human rAGR2, but only weakly with the 19kDa His-tagged
human rAGR3, the ratio of intensities AGR2:AGR3 being
10.271.3 (mean7s.d.) for equal amount of recombinant protein
loaded onto the gel (Figure 2B). A band corresponding to normal
AGR3 was not detected in human cell extracts with this
antibody (Figure 2A).
Quantitative RT–PCR was performed on 84 of the above cases.
The relative abundance of AGR2 mRNA correlated significantly
with the class score for immunocytochemically detectable AGR2
protein in the cancer cells (Spearman’s rank correlation statistic
0.36; P¼0.0007). Furthermore, significantly higher AGR2 mRNA
expression was seen in those cases that were AGR2 positive by
immunohistochemistry compared to those that were AGR2
negative (Student’s t-test, P¼0.010; Mann–Whitney U-test,
P¼0.001; Figure 2C). Thus, the percentage of carcinoma cells
stained immunocytochemically in the primary tumours was a
reasonable reflection of the level of expression of AGR2 mRNA and
protein.
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sAssociation of staining for AGR2 with other tumour
variables
The presence of immunocytochemical staining for AGR2 was
cross-tabulated with the established prognostic factors of tumour
size, nodal status, histological grade, lymphovascular invasion,
ERa and PgR status (Table 2). For these analyses, the borderline
staining group was combined with the positive staining group for
AGR2, that is, using a 1% cutoff of the carcinoma cells staining
(Materials and Methods). Positive staining for AGR2 was
significantly correlated with that for the ERa receptor (Fisher’s
Exact test, Po0.0001) and with that for the PgR receptor (Fisher’s
Exact test, P¼0.0002). Staining for AGR2 was also significantly
associated with low tumour grade (Fisher’s Exact test, Po0.0001).
As expected, ERa positivity was significantly associated with low
tumour grade (Fisher’s Exact test, Po0.0001): 177 of 220 (80.5%)
ERa-positive tumours were grade 1 or 2, compared to 42 of 115
(36.5%) ERa-negative tumours. Positive staining for AGR2 was not
significantly associated with tumour size, nodal status or the
presence of lymphovascular invasion (Table 2). There was also no
significant association between positive staining for ERa and either
tumour size or nodal status (not shown). If the borderline staining
group were combined with the negative staining group (i.e. using a
5% cutoff) for AGR2, the same significant associations were seen.
Within the ERa-negative group, there was a positive correlation
between the degree of staining for AGR2 (41% carcinoma cells
A
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E
G
B
F
D
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n
n
nn
n
Figure 1 Immunocytochemical staining for AGR2. Antiserum to AGR2 was incubated with histological sections of specimens from (A) normal breast or
from (B–D) primary tumours of different breast carcinomas showing: (B) unstained ( ); (C) borderline (7); (D) strong immunocytochemical staining of
the carcinoma cells (þþþ). Arrows point to the occasional stained cell in C; n is unstained normal breast tissue in D.( E) is a higher magnification of D
showing strong immunocytochemical staining of the cytoplasm (arrowheads) and membranous region (arrows) of the carcinoma cells. (F) Antiserum to
AGR2 preincubated with pure human rAGR2 applied to an adjacent serial section to that in E showing no immunocytochemical staining. (G) Antiserum to
AGR2 preincubated with pure human rAGR2 showing no immunocytochemical staining over a larger field at lower magnification to that in F.( H) Antiserum
to AGR2 preincubated with pure human rAGR3 showing strong immunocytochemical staining of the carcinoma cells in a section adjacent to that in G, the
normal breast tissue n is unstained. Magnification A–D, G, H  230; E, F  580. Bars A–D, G, H 50mm; E, F 20mm.
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sstained) and the degree of staining for PgR (n¼47 cases;
Spearman’s correlation coefficient 0.48; P¼0.0007).
Association of AGR2 with patient survival
In the whole group, there was no significant association between
staining for AGR2 and patient survival (Figure 3A log rank test,
P¼0.33; Wilcoxon test, w
2¼0.05, 1d.f., P¼0.82). However, when
ERa-positive cases were considered separately (n¼225), there was
a strong negative correlation between the presence of AGR2
staining (using a 1% cutoff of the carcinoma cells stained) and
patient survival, with patients whose tumours were AGR2 positive
having significantly poorer survival than those whose tumours
were AGR2 negative (Figure 3B; log rank test, P¼0.007; Wilcoxon
test, w
2¼6.0, 1d.f., P¼0.01). Median survival for this ERa
positive cohort has not yet been reached for either AGR2-positive
or AGR2-negative patients. The HR for survival of patients with
AGR2-positive tumours compared to AGR2-negative tumours was
3.0 (95% CI 1.3–6.9). This difference in survival is a relatively late
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Figure 2 Detection of AGR2 by Western blotting and RT–PCR. (A)
Protein samples (20mg) from invasive carcinomas of the following classes of
immunocytochemical staining for AGR2: unstained ( ; lane 1), borderline
(7; lanes 2 and 3), moderate (þþ; lane 4), strong (þþþ; lane 5), very
strong (þþþþ; lanes 6 and 7), and 10mg of protein from human breast
cancer cell line, MCF-7 (lane 8) or 0.5mg of purified His-tagged rAGR2
(lane 9) were subjected to polyacrylamide gel electrophoresis and blotted
onto Immobilon PVDF membranes as described in Materials and Methods.
The membranes were incubated overnight at 41C with one of the
following: a 1:400 dilution of rabbit polyclonal anti-human AGR2 (A, upper
panel), the same amount of rabbit polyclonal anti-human AGR2
preincubated overnight at 41C with 1mgml
 1 human rAGR2 (A, middle
panel) and 1:1000 dilution of rabbit anti-b-actin antibodies (A, lower
panel). The positions of human natural AGR2 (nAGR2), recombinant His-
tagged AGR2 (rAGR2) and actin are shown on the right-hand side of the
panels and those of molecular weight markers are shown on the left-hand
side of the panels. (B)5mg( B, SDS-PAGE panel) or 0.5mg( B, Western
blot panels) of purified His-tagged rAGR2 and His-tagged rAGR3 were
subjected to 12.5% (wv
 1) polyacrylamide SDS gel electrophoresis and
stained with Coomassie blue G250 (B, SDS-PAGE panel) or blotted onto
an Immobilon PVDF membrane (B, Western blot panels) as described in
Materials and Methods. The membrane was incubated with one of the
following: a 1:500 dilution of rabbit polyclonal anti-human AGR2 (B,
Western blot 1 (AGR2 Ab) panel), the same amount of rabbit polyclonal
anti-human AGR2 preincubated overnight at 41C with 1mgml
 1 human
rAGR3 protein (B, Western blot 2 (blocked with rAGR3) panel), and the
bound antibodies visualized as above. The positions of rAGR2 and rAGR3
are shown on the right-hand side of the panel and those of molecular
weight markers are shown on the left-hand side. (C) Relative expression of
AGR2 mRNA is shown in four categories of breast tumours: a, patients
with carcinomas classified as unstained ( ); b, borderline (7); c,
intermediate (þ)o rd, moderate to very strong staining for AGR2
(þþ, þþþor þþþþ). AGR2 mRNA was determined by qRT–
PCR and is shown relative to that in MCF-7 cells (ddCt relative to MCF-7)
as described in Materials and Methods. The box represents the interquartile
range, the line across the box indicates the median and the whiskers extend
from the box to the highest and lowest values (excluding outliers and
extreme points).
Table 2 Association of immunohistochemical staining for AGR2 with
other tumour variables
Tumour
variable
a
AGR2-positive
b
no. (%)
AGR2-negative
b
no. (%)
Statistical
significance
c
Grades 1, 2 178 (79.1) 46 (39.0)
Grade 3 47 (20.9) 72 (61.0) o0.0001
T1 120 (55.3) 61 (53.0)
T2, T3 97 (44.7) 54 (47.0) 0.73
ERa negative 38 (17.0) 79 (66.4)
ERa positive 185 (83.0) 40 (33.6) o0.0001
Node negative 96 (57.5) 45 (57.0)
Node positive 71 (42.5) 34 (43.0) 1
LVI negative 84 (54.2) 38 (51.4)
LVI positive 71 (45.8) 36 (48.6) 0.78
PgR negative 44 (46.3) 35 (79.5)
PgR positive 51 (53.7) 9 (20.5) 0.0002
aGrades, 1 and 2 vs 3; tumour size, T1 vs T2 and T3; oestrogen receptor a negative
(ERa-negative) vs positive; lymph nodes containing no tumour, node negative vs
positive; no lymphovascular invasion (LVI) negative vs positive; progesterone
receptor-negative (PgR-negative) vs positive.
bNumbers (percentage) of patients
with tumours staining (positive) or not staining (negative) for AGR2.
cProbability, P,
from Fisher’s Exact test.
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seffect, with the survival curves beginning to diverge at approxi-
mately 40 months of follow-up, and the difference in overall
survival becoming significant at 6 years. If the borderline staining
group were combined with the negative staining group (i.e. using a
5% cutoff of the carcinoma cells stained), a significant association
between staining for AGR2 and patient demise was also observed
(log rank test, P¼0.01; Wilcoxon test, w
2¼6.2, 1d.f., P¼0.01)
with an unadjusted HR of 1.9 (95% CI 1.1–3.2). When the
ERa-positive cases were further divided into separate classes
based on the percentage of carcinoma cells stained (o1%, 1–5,
5–25 and 425% positive cells), the four curves showed
significantly progressively poorer survival (Figure 3C; log rank
test, P¼0.006; Wilcoxon test w
2¼10.12, 3d.f., P¼0.02). Notably,
cases with o1% cells staining had significantly better survival
than cases with 5–25% positive cells (log rank test, P¼0.03;
Wilcoxon test w
2¼4.2, 1d.f., P¼0.04) and cases with 425%
positive cells staining (log rank test, P¼0.0006; Wilcoxon test
w
2¼8.7, 1d.f., P¼0.003). When ERa-negative cases were con-
sidered separately, there was no significant association between
staining for AGR2 and survival (log rank test, P¼0.85; Wilcoxon
test w
2¼0.2, 1d.f., P¼0.66).
Association of other tumour variables and AGR2 with
patient survival
The established prognostic markers behaved in the expected
manner with respect to patient overall survival, with positive nodal
status, larger tumour size and high histological grade all associated
with significantly poorer patient survival at 10 years of follow-up
(log rank test, all Po0.0001). Oestrogen receptor a-negative status
was not significantly associated with poorer patient survival at 10
years of follow-up (log rank test, P¼0.1), as the survival curves
had begun to converge, but was statistically significant at earlier
time points (from 18 months to 8 years, log rank rest, Po0.04, e.g.
at 3 years P¼0.0006).
Within the ERa-positive group of patients, the association
between immunocytochemical staining for AGR2 (at the 1% cut-
off level) and patient survival was assessed further within
subgroups defined by the other tumour variables. Staining for
AGR2 was associated with poorer survival of patients with smaller
tumours (T1 tumours n¼117; log rank test, P¼0.007; Wilcoxon
test w
2¼7.6, 1d.f., P¼0.006), but not with patients with larger
tumours (TX2, n¼94, log rank test, P¼0.6; Wilcoxon test
w
2¼0.02, 1d.f., P¼0.9). As expected, the majority of the
1.0
0.8
0.6
0.4
0.2
0
02468 1 0
a
a
b
b
a
b
c
d
Survival time (years)
p
r
o
p
o
r
t
i
o
n
 
s
u
r
v
i
v
i
n
g
C
u
m
u
l
a
t
i
v
e
 
o
v
e
r
a
l
l
1.0
0.8
0.6
0.4
0.2
0
p
r
o
p
o
r
t
i
o
n
 
s
u
r
v
i
v
i
n
g
C
u
m
u
l
a
t
i
v
e
 
o
v
e
r
a
l
l
1.0
0.8
0.6
0.4
0.2
0
p
r
o
p
o
r
t
i
o
n
 
s
u
r
v
i
v
i
n
g
C
u
m
u
l
a
t
i
v
e
 
o
v
e
r
a
l
l
N=
120 115 101 94 83 77 68 63 58 49 37 a
231 225 211 194 172 149 137 117 98 75 50 b
02468 1 0
Survival time (years) N=
024681 0
Survival time (years) N=
40 40 39 38 32 29 26 24 24 19 16 a
185 180 169 158 138 120 108 90 74 58 38 b
40 40 39 38 32 29 26 24 24 19 16 a
46 45 42 41 36 29 27 22 19 14 8 b
79 78 73 67 63 57 54 47 39 33 25 c
60 57 54 50 39 34 27 21 16 11 5 d
A
B
C
Figure 3 Association of immunocytochemical staining for AGR2 with
overall survival of patients using a 1% cutoff between the two staining
classes for (A) all cases, (B)E R a-positive cases or (C) by degree of
immunostaining for AGR2 in ERa-positive cases. In (A and B), the
cumulative proportion of surviving patients as a fraction of the total for
each year after presentation for either a patients with carcinomas classified
as negatively staining (black, unbroken line) or b positively staining (grey
broken line) for AGR2 is shown. In (A), there were 81 censored
observations in a and 139 in b. The cumulative proportions surviving were
a, 0.71 at 5 years (standard error (s.e.)¼0.04) and 0.64 at 10 years
(s.e.¼0.05) and b, 0.69 at 5 years (s.e.¼0.06) and 0.54 at 10 years
(s.e.¼0.04). In (B), there were 34 censored observation in a and 114 in b.
The cumulative proportions surviving were a 0.87 at 5 years (s.e.¼0.05)
and 0.82 at 10 years (s.e.¼0.07) and b 0.81 at 5 years (s.e.¼0.06) and
0.60 at 10 years (s.e.¼0.09). In (C), the cumulative proportion of surviving
patients with ERa positive primary tumours for a patients with carcinoma
cells classified as unstained (black, unbroken line), b borderline (7, black
broken line), c intermediate (þ, grey unbroken line) or d moderate to very
strong staining for AGR2 (þþ, þþþor þþþþ, grey broken line)
is shown. There were 34 censored observations in a;3 2i nb;5 0i nc and 32
in d. The cumulative proportions surviving were a 0.87 (s.e.¼0.05); b 0.81
(s.e.¼0.06), c 0.73 (s.e.¼0.05) and d 0.59 (s.e.¼0.07) at 5 years; and a
0.82 (s.e.¼0.07); b 0.60 (s.e.¼0.09); c 0.59 (s.e.¼0.06) and d 0.39
(s.e.¼0.09) at 10 years. In all three panels, censored observations are
denoted by vertical lines and the number of surviving patients in each
subgroup (N) at 12 monthly intervals is shown below each panel.
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subgroup staining for AGR2 was also associated with poorer
patient survival (log rank test, P¼0.009; Wilcoxon test w
2¼5.8,
1d.f.; P¼0.02). In the small number of patients with ERa-positive
grade 3 tumours (n¼43), there was a trend for AGR2 to be
associated with poorer survival, but this did not reach statistical
significance (log rank test, P¼0.1; Wilcoxon test w
2¼1.9, 1d.f.,
P¼0.2). There was no significant difference in patient survival by
AGR2 staining in ERa-positive patients when subdivided by nodal
status (node negative, n¼94; log rank test, P¼0.34; Wilcoxon test
w
2¼0.56, 1d.f., P¼0.5; node positive, n¼63; log rank test,
P¼0.46; Wilcoxon test w
2¼0.03, 1d.f., P¼0.9). In Cox’s multi-
variate analysis of the 114 patients available with full data sets
(size, grade, nodal status, presence or absence of lymphovascular
invasion and AGR2 staining) in the ERa-positive group, only nodal
status was independently significantly correlated with patient
survival (w
2¼6.75, 1d.f., P¼0.009). The AGR2 was significantly
associated with patient survival when considered pair-wise with
tumour size (AGR2 HR 2.7, 95% CI 1.2–6.2, P¼0.02, size HR 1.6,
95% CI 1.02–2.6, P¼0.04) or pair-wise with grade (AGR2 HR 3.6,
95% CI 1.5–8.4, P¼0.003, grade HR 2.5 95% CI 1.5–4.2,
P¼0.001).
DISCUSSION
The developmentally related protein AGR2 has been shown, in a
rat mammary model, to induce a metastatic phenotype (Liu et al,
2005). Preliminary studies have also indicated that expression of
this protein is correlated with ERa expression in human breast
cancer cell lines (Thompson and Weigel, 1998; Liu et al, 2005) and
clinical specimens (Fletcher et al, 2003). In order to assess the
relationship of AGR2 with other tumour variables including ERa
and with patients’ survival, we have examined the immunohisto-
chemical expression of AGR2 in specimens of 351 primary breast
carcinomas taken from patients who received no chemotherapy,
but the vast majority (93%) of whom were given some form of
endocrine treatment, usually tamoxifen post operatively (Table 1).
Immunocytochemical staining was almost completely restricted to
the cytoplasm and membranous region of malignant cells, and
there was virtually no staining for AGR2 of normal host
parenchymal or stromal tissues, consistent with previous studies
(Fletcher et al, 2003; Liu et al, 2005). Overall, 64.8% of breast
cancers stained for AGR2 using a 1% cutoff to differentiate the
negatively and positively staining tumours. This value is a little
lower than the staining levels found in pilot studies: 75% using the
same antibody (Liu et al, 2005) and 83% using a different antibody
(Fletcher et al, 2003).
The specificity of staining for AGR2 in the clinical samples has
been verified in 20 randomly selected cases by obtaining the same
results when the concentration of antibody is increased five-fold,
when another batch of antiserum raised in a different rabbit is
employed and by the abolition of staining by prior incubation of
the antiserum with pure recombinant protein. Moreover, when
tested by Western blotting techniques, the rabbit antiserum reacts
with only a single band of 18kDa in extracts of selected positively
staining carcinomas and in the breast cancer cell line MCF-7, in
agreement with previous results for AGR2 (Liu et al, 2005).
Although the rabbit antibody to AGR2 also crossreacts to a very
limited extent by Western blotting with AGR3, the immunocyto-
chemical staining observed arises almost exclusively from AGR2
and not from any potential AGR3 for the following reasons: (1)
The MAb which is entirely specific for AGR2 and does not
crossreact with AGR3 yields the same staining classification for 20
specimens selected at random. (2) Prior incubation of the rabbit
antiserum with pure human rAGR3 fails to abolish any staining.
(3) No band corresponding to AGR3 is detectable in human cell
extracts with this antibody.
Using the rabbit antibody to AGR2, the interobserver and
intraobserver variability in immunocytochemical staining ob-
served between the negatively and positively staining groups is
sufficiently small (2.6 and 2.8%, respectively) not to affect
appreciably the reported results. The different classes of immu-
nocytochemical staining of the carcinoma specimens based on the
proportion of AGR2 immunoreactive carcinoma cells may also
reflect the levels of expressed AGR2 protein, because the levels of
AGR2 immunoreactive protein, as determined by Western
blotting, are linearly correlated with the percentage of stained
carcinoma cells by immunocytochemistry in the limited number of
specimens studied. Moreover, expression of AGR2 as measured by
immunocytochemistry correlates well with quantitative RT–PCR
measurement of the abundance of AGR2 mRNA. This indicates
that mRNA production is probably the primary control point for
expression of AGR2 and is consistent with the mRNA-based
subtractive hybridisation approach used to first identify AGR2 as a
potential marker of aggressive ERa-positive tumours (Liu et al,
2005).
In specimens from the 351 breast carcinomas, there was a strong
positive association between the presence of immunocytochemical
staining for AGR2 and for ERa. Moreover, within the ERa-negative
group of tumours, staining for AGR2 was positively correlated with
staining for PgR. These findings are consistent with our cell line
data in which AGR2 mRNA is present at much higher levels
(seven-fold greater), in oestrogen-responsive MCF-7 cells grown in
the presence of oestrogen than in oestrogen-depleted conditions
(Liu et al, 2005) and with other studies (Thompson and Weigel,
1998; Fletcher et al, 2003), and are strongly indicative of AGR2
being an ER-dependent gene. In turn, the relationships between
AGR2 and other tumour variables reflected this strong association
with ERa positivity; thus, staining for AGR2 is associated with
tumours of lower grade but not with tumour size, nodal status or
the presence of lymphovascular invasion. However, since almost a
third of ERa-negative cases stained for AGR2 and not all ERa-
positive cases stained for AGR2, other factors must also influence
expression of AGR2. Previously we had shown that AGR2 can
increase adhesion of Rama 37 cells either when directly added or
when overexpressed after transfection with an expression vector
for AGR2 (Liu et al, 2005). However, no attempts have been made
to investigate the effect of oestrogen on cellular adhesion in MCF-7
cells, since the production of another adhesion-inducing molecule,
osteopontin (Moye et al, 2004), in addition to AGR2, is also
stimulated by oestrogen (El-Tanani et al, 2001), so complicating
interpretation of the results.
The finding that in the whole patient group there is no
significant association between staining for AGR2 and patient
outcome is also consistent with a role for AGR2 not solely related
to ERa, since ERa-positive status is itself associated with a better
patient outcome. That AGR2 has potential as a marker indepen-
dent of ERa is confirmed by our findings when the ERa-positive
and ERa-negative patient subgroups are considered separately. In
the ERa-positive group, positive staining for AGR2 is associated
with significantly poorer patient survival than that of the AGR2-
negative group, with an unadjusted HR of 3. Moreover, when the
ERa-positive cases are subdivided into separate classes by
increasing proportion of carcinoma cells staining for AGR2, the
survival curves showed progressively poorer survival. Thus, there
appears to be a ‘dose response’ relationship between the % cell
staining for AGR2 and adverse impact on patient outcome in the
ERa-positive group of tumours. The fact that overexpression of
AGR2 in benign rat mammary cells causes them to metastasise in
syngeneic rats in vivo (Liu et al, 2005), but the human breast
cancer cell line isolated from a metastatic plural effusion (Soule
et al, 1973) fails to exhibit aggressive behaviour in vitro and to
metastasise in vivo (Clarke et al, 1990) despite expressing AGR2, is
at first sight surprising. However, MCF-7 cells when exposed to
high levels of oestrogens which induce increased levels of AGR2
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can form tumours and metastases in nu nu mice in vivo (Clarke
et al, 1994; Kern et al, 1994). Moreover, the immunodeficient
rodent is a poor model for breast cancer metastasis, since T-cell-
depleted rats fail to allow the formation of tumours and metastases
from a rat cell line that is highly metastatic in the same immune-
competent intact rats (Rudland et al, 1989).
The differential impact of staining for AGR2 on prognosis in
ERa-positive and ERa-negative patients is in contrast to the
adverse effect of staining for S100A4 and OPN on the survival of
patients with breast cancer which are apparent in both ERa-
positive and ERa-negative subgroups (Rudland et al, 2000, 2002).
These proteins were identified as inducers of the metastatic
phenotype in experiments similar to those performed for AGR2
(Davies et al, 1993; Oates et al, 1996). However, upon transfection
of an expression vector for AGR2 into parental Rama 37 cells and
their transplantation into syngeneic rats, the primary tumours
appear on average with an increased latency compared to that for
S100A4-transfected, osteopontin-transfected or the parental Rama
37 cells (Davies et al, 1993; Oates et al, 1996; Liu et al, 2005).
Nevertheless, this average slower tumour growth does not hinder
the ability of AGR2-transfected cells to form metastases, it merely
delays it. It is tempting to speculate that a similar effect of AGR2 in
human tumours may account for the late effect on patient outcome
found in the ERa-positive group in this study; the survival curves
do not begin to separate until approximately 40 months and
become significant only at 6 years. Since breast cancer relapses in
ERa-positive patients often occur late (Saphner et al, 1996), this
finding may be of clinical relevance, particularly in relation to
consideration of extended adjuvant endocrine therapy in such
patients. It may further be suggested that the absence of an impact
of staining for AGR2 on prognosis in ERa-negative patients may be
related to the higher proliferation rate of their tumours and
tendency to earlier metastasis, with other genes/gene products
having a greater influence on patient outcome.
An additional explanation for the differential prognostic impact
of AGR2 on ERa-positive and ERa-negative subgroups of tumours
may relate to the treatment received by these patients. The
majority have received adjuvant endocrine therapy (predomi-
nantly tamoxifen), which would be expected to have an effect on
ERa-positive but not ERa-negative patients. AGR2 mRNA is
present at much higher levels (seven-fold greater) in oestrogen-
responsive MCF-7 cells grown in the presence of oestrogen than in
cells grown in oestrogen-depleted conditions (Liu et al, 2005).
Therefore, it may be expected that the expression of AGR2 would
be suppressed by the anti-oestrogenic effects of tamoxifen. In this
group of patients, tamoxifen was usually given for between 2 and 5
years and therefore the apparent separation of the survival curves
at around 3–4 years in ERa-positive patients would be consistent
with the removal of adjuvant hormonal therapy resulting in the
adverse re-expression of AGR2.
Our results demonstrate that expression of AGR2, as measured
by immunohistochemistry, is associated with poor outcome in
patients with ERa-positive breast cancers. Further studies are
required to characterise this relationship, particularly with regard
to how ERa induces the expression of AGR2 and the exact
mechanism of AGR2 in the metastatic process. It is to be hoped
that knowledge of expression of AGR2 may, in the future, help to
inform treatment decisions for patients with ERa-positive breast
cancers in the adjuvant or extended adjuvant settings.
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